MIRM

97.0701.63%
EH

Eric H. Bjerkholt

Chief Financial Officer

Mr. Eric H. Bjerkholt, MBA, M.S., is Independent Director of Metagenomi Therapeutics, Inc. (formerly known as Metagenomi, Inc.) from January 27, 2025. He serves as Chief Financial Officer of Mirum Pharmaceuticals, Inc. since September 11, 2023. He served as Chairman of the Board of Altay Therapeutics Inc. until 2025 and serves as its Board Member. He is Independent Director of Surrozen, Inc. from April 2023. He served as an Independent Non-Employee Director at CalciMedica, Inc. (formerly known as Graybug Vision, Inc.) since September 2020 until 2025. He served as Chief Financial Officer of Chinook Therapeutics, Inc. since November 2020 until August 11, 2023. Mr. Bjerkholt is Independent Director of Cerus Corporation since March 29, 2024. He was Independent Director at Cerus Corporation since October 9, 2018 until January 25, 2021. He was Director of Cerus Corporation since January 25, 2021 until March 29, 2024. Mr. Bjerkholt served as Chief Financial Officer of Aimmune Therapeutics, Inc. from April 13, 2017 until October 13, 2020. Mr. Bjerkholt commenced employment with Aimmune in April 2017. From 2004 until April 2017, Mr. Bjerkholt held various roles at Sunesis Pharmaceuticals, Inc. Mr. Bjerkholt served as the Chief Financial Officer of Sunesis Pharmaceuticals, Inc. from January 2004 to April 27, 2017 and its Executive Vice President of Corporate Development & Finance from February 2, 2012 to April 27, 2017, where, his role expanded to oversee business development and multiple aspects of governance and corporate relations. He served as Secretary of Sunesis Pharmaceuticals, Inc. until April 27, 2017 and previously served as its Senior Vice President of Corporate Development and Finance from February 2007 to January 2012. He served as Principal Accounting Officer of Sunesis Pharmaceuticals, Inc. He has health care and biotechnology leadership experience in finance and related functions, both as an executive at publicly traded and early-stage companies and as an investment banker. At Sunesis, Mr. Bjerkholt leads the financial operations, public and Investor Relations and treasury activities of the South San Francisco small molecule biopharmaceutical company. He served as Senior Vice President at Sunesis Pharmaceuticals Inc., from January 2004 to January 2007. Before joining Sunesis, he served as Chief Financial Officer and Senior Vice President of Intrabiotics Pharmaceuticals Inc., from January 10, 2002 to January 2004. He co-founded LifeSpring Nutrition, Inc. and from May 1999 to March 2002 and served as its Chief Executive Officer, President and Chief Financial Officer. He co-founded LifeSpring Home Nutrition in 2003 and served as its Chief Financial Officer. From 1997 to 1999, he served as an Executive Vice President, Finance & Strategic Operations at AgeWave LLC. He began his healthcare career at J.P. Morgan & Co. as an Investment Banker in New York and then launched its Western U.S. healthcare practice. Mr. Bjerkholt has experience in healthcare investment banking, including Vice President of J.P. Morgan & Co. Inc. from 1990 to 1997, where he was responsible for a large number of equity and other transactions in the biotechnology, pharmaceutical and other healthcare sectors. He has also held appointments as Senior Economist with the Norwegian Ministry of Finance and as an Economist with the United Nations. He served as an Independent Director of Corium International, Inc. since April 1, 2015 until November 27, 2018. He has served on the boards of Directors of several publicly traded companies. He served as a Director of Ambrx, Inc. since May 2014 and StemCells Inc. since March 1, 2004 until November 2016. Mr. Bjerkholt holds an M.B.A. from Harvard Business School and a Candy. Oecon. (master's) Degree in Mathematical Economics and Econometrics from the University of Oslo, Norway.

Positions